Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F Finzi

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|October 28, 1982
Low levels of HDL in severe cystic acneC Vergani, A F Finzi, P D Pigatto, et al.
Cancer|November 15, 1994
Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastineL Brambilla, R Labianca, V Boneschi, et al.
Dermatologica|January 1, 1986
Isotretinoin versus minocycline in cystic acne: a study of lipid metabolismP D Pigatto, A F Finzi, G F Altomare, et al.
The British Journal of Dermatology|May 1, 1986
Complement cleavage products in the phototoxic reaction of porphyria cutanea tardaP D Pigatto, M M Polenghi, G F Altomare, et al.
The Journal of Investigative Dermatology|November 1, 1983
Effect of etretinate on chemotaxis of neutrophils from patients with pustular and vulgar psoriasisP D Pigatto, F Riva, G F Altomare, et al.
Journal of the American Academy of Dermatology|April 1, 1989
Circadian rhythm of natural killer cell activity in vitiligoN Mozzanica, U Frigerio, M Negri, et al.
Journal of the American Academy of Dermatology|May 1, 1992
Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligoN Mozzanica, M L Villa, S Foppa, et al.
Journal of the American Academy of Dermatology|February 1, 1990
T cell subpopulations in vitiligo: a chronobiologic studyN Mozzanica, U Frigerio, A F Finzi, et al.
Acta Dermato-Venereologica|January 1, 1987
Histological and immunological features of primary Kaposi's sarcoma: evaluation before and after chemotherapyL Brambilla, V Boneschi, P D Pigatto, et al.
Dermatology (Basel, Switzerland)|August 18, 1999
Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM)H P Gollnick, A F Finzi, R Marks, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|October 28, 1982
Low levels of HDL in severe cystic acneC Vergani, A F Finzi, P D Pigatto, et al.
Cancer|November 15, 1994
Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastineL Brambilla, R Labianca, V Boneschi, et al.
Dermatologica|January 1, 1986
Isotretinoin versus minocycline in cystic acne: a study of lipid metabolismP D Pigatto, A F Finzi, G F Altomare, et al.
The British Journal of Dermatology|May 1, 1986
Complement cleavage products in the phototoxic reaction of porphyria cutanea tardaP D Pigatto, M M Polenghi, G F Altomare, et al.
The Journal of Investigative Dermatology|November 1, 1983
Effect of etretinate on chemotaxis of neutrophils from patients with pustular and vulgar psoriasisP D Pigatto, F Riva, G F Altomare, et al.
Journal of the American Academy of Dermatology|April 1, 1989
Circadian rhythm of natural killer cell activity in vitiligoN Mozzanica, U Frigerio, M Negri, et al.
Journal of the American Academy of Dermatology|May 1, 1992
Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligoN Mozzanica, M L Villa, S Foppa, et al.
Journal of the American Academy of Dermatology|February 1, 1990
T cell subpopulations in vitiligo: a chronobiologic studyN Mozzanica, U Frigerio, A F Finzi, et al.
Acta Dermato-Venereologica|January 1, 1987
Histological and immunological features of primary Kaposi's sarcoma: evaluation before and after chemotherapyL Brambilla, V Boneschi, P D Pigatto, et al.
Dermatology (Basel, Switzerland)|August 18, 1999
Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM)H P Gollnick, A F Finzi, R Marks, et al.
Pageof 7